Concentra Group Holdings Parent, Inc. (CON) Fair Value & Analysis
Healthcare · US · Market cap $4.0B · ISIN US20603L1026
What is Concentra Group Holdings Parent, Inc. really worth?
Concentra Group Holdings Parent, Inc.
CON · US
A solid business, but trading 25% above our fair value of $27.71.
Risks
For context
Fair value as of: Aug 19, 2026
From 26 valuation models · updated 16 days ago
Share price +10.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The model range is unusually wide ($10.63 to $50.13). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
25‑month range $18.56 – $35.53 · fair‑value band $10.63 – $50.13 · the $34.51 price screens above the $27.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Concentra Group Holdings Parent, Inc. (CON) currently trades at $34.51, while our model-based Fair Value estimate is $27.71, implying the stock looks roughly 24.5% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $26.86 per share, and 0 of the 26 models we run sit above the $34.51 price. Bear case: the Dividend Discount group reads lowest at $3.70, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Concentra Group Holdings Parent, Inc. generated revenue of $2.2B at a net margin of 8.0%. Revenue grew 13.7% year over year. It earns a return on equity of 47.0%. Net debt stands at $2.0B. Fundamentals as of Aug 19, 2026
Our scenario range runs from $10.63 (bear case) to $50.13 (bull case); at $34.51, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 88% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −20%, CON screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.7715 per share, which is 2.8 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth Earnings ($26.86) versus Asset-Based ($2.06). Highest evidence: EPV (73).
Notify me when CON reaches fair value
Put CON on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 85
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business.
Full company description
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business. It offers occupational health services, including workers compensation, employer, and consumer health services; and employer-sponsored primary care services at workplace, including mobile health and episodic specialty testing services. It also operates Concentra Telemed, a telemedicine platform for the treatment of work-related injuries and illnesses; Concentra Pharmacy for distributing repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. In addition, the company provides injury care, primary care, urgent care, preventive care, clinical testing, physical examinations and evaluations, drug and alcohol screenings, clinical testing, vaccinations and other preventive care, and a range of consultative services designed to protect employees from workplace hazards. The company was founded in 1979 and is based in Addison, Texas.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Concentra Group Holdings Parent, Inc. reported revenue of $2.2B in FY2025 versus $1.7B in FY2021, a compound +5.7%/yr. Reported net income was $173M in FY2025, compounding −4.6%/yr from FY2021.
CON screens 25% overvalued. Compare with HCA Healthcare, Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- CON vs. MEDP: Which Stock Should Value Investors Buy Now?
- Concentra Group (CON) is a Great Momentum Stock: Should You Buy?
- Concentra Appoints Dr. Jill Rosenthal as Chief Medical Officer to Advance Clinical Innovation and Workforce Health
- Concentra Strengthens Workforce Health Access in Minnesota Through Acquisition
Peer Group
Medical Care Facilities · 256 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $417.82 | $547.67 | +31% |
| Fresenius SE FRE | €45.25 | €32.15 | −29% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 241.00 SAR | 112.37 SAR | −53% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | −46% |
| Tenet Healthcare Corporation THC | $266.80 | $330.25 | +24% |
| DaVita Inc DVA | $180.68 | $186.49 | +3% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | −66% |
| Fresenius Medical Care AG FME | €39.92 | €71.28 | +79% |
| Aier Eye Hospital Group 300015 | ¥8.25 | ¥7.67 | −7% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,005 | ₹284.87 | −72% |
Compare Concentra Group Holdings Parent, Inc. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Concentra Group Holdings Parent, Inc. (CON) overvalued or undervalued?
What is the fair value of CON?
What is the quality score of CON?
What is the revenue of Concentra Group Holdings Parent, Inc. (CON)?
What is the net profit margin of CON?
Does Concentra Group Holdings Parent, Inc. pay a dividend?
Watch Concentra Group Holdings Parent, Inc. in the live analysis
One click puts Concentra Group Holdings Parent, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.